DE2145325A1 - Verfahren zur Herstellung einer Arzneimittelz ubereitung - Google Patents
Verfahren zur Herstellung einer Arzneimittelz ubereitungInfo
- Publication number
- DE2145325A1 DE2145325A1 DE19712145325 DE2145325A DE2145325A1 DE 2145325 A1 DE2145325 A1 DE 2145325A1 DE 19712145325 DE19712145325 DE 19712145325 DE 2145325 A DE2145325 A DE 2145325A DE 2145325 A1 DE2145325 A1 DE 2145325A1
- Authority
- DE
- Germany
- Prior art keywords
- urethane
- drug
- pvp
- solution
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 52
- 239000003814 drug Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 43
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 37
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 32
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 7
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 claims description 5
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 claims description 5
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 claims description 5
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 claims description 5
- 229960002867 griseofulvin Drugs 0.000 claims description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 4
- VDDAVZWCRBHDLQ-UHFFFAOYSA-N 2-phenylquinazoline Chemical class C1=CC=CC=C1C1=NC=C(C=CC=C2)C2=N1 VDDAVZWCRBHDLQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003133 ergot alkaloid Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 22
- 239000008101 lactose Substances 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 3
- JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229960002614 lanatoside c Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical group N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7282970A | 1970-09-16 | 1970-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2145325A1 true DE2145325A1 (de) | 1972-03-23 |
Family
ID=22110005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712145325 Pending DE2145325A1 (de) | 1970-09-16 | 1971-09-10 | Verfahren zur Herstellung einer Arzneimittelz ubereitung |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU3351771A (enrdf_load_stackoverflow) |
| BE (1) | BE772594A (enrdf_load_stackoverflow) |
| DE (1) | DE2145325A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2106553A1 (enrdf_load_stackoverflow) |
| NL (1) | NL7112288A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7314765A (enrdf_load_stackoverflow) * | 1972-10-31 | 1974-05-02 | ||
| US4195078A (en) * | 1979-03-09 | 1980-03-25 | Eli Lilly And Company | Nabilone granulation |
-
1971
- 1971-09-07 NL NL7112288A patent/NL7112288A/xx unknown
- 1971-09-10 DE DE19712145325 patent/DE2145325A1/de active Pending
- 1971-09-14 BE BE772594A patent/BE772594A/xx unknown
- 1971-09-15 FR FR7133150A patent/FR2106553A1/fr not_active Withdrawn
- 1971-09-15 AU AU33517/71A patent/AU3351771A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| BE772594A (fr) | 1972-03-14 |
| AU3351771A (en) | 1973-03-22 |
| FR2106553A1 (en) | 1972-05-05 |
| NL7112288A (enrdf_load_stackoverflow) | 1972-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3224619C2 (enrdf_load_stackoverflow) | ||
| DE69311395T2 (de) | Sphäroidische Arzneimittelformulierung | |
| DE69004372T2 (de) | Verfahren zum Mikronisieren schwerlöslicher Arzneistoffe. | |
| DE3437599C2 (de) | Ibuprofen enthaltende Weichgelatinekapseln | |
| DE3877331T2 (de) | Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung. | |
| DE69213836T2 (de) | Megestrolazetat-Formulierung | |
| DE3124014A1 (de) | Aluminiumibuprofensuspensionen | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE68906765T2 (de) | Zusammensetzung mit einem extrakt,das durch extraktion mit einem wasserhaltigen organischen loesungsmittel erhalten wurde und verfahren zu seiner herstellung. | |
| DE69221150T2 (de) | Pharmakologisch verbesserte formulierungen | |
| DE3503679A1 (de) | Pharmazeutische zusammensetzungen | |
| DE68914683T2 (de) | Arzneimittelzusammensetzung für die schnelle verabreichung des aktiven bestandteils, der aus einer festen dispersion und einem oberflächenaktiven mittel besteht. | |
| DE3878978T2 (de) | Galenische form eines trockenextraktes von pflanzen. | |
| DE100061T1 (de) | Kombinierte pharmazeutische zusammensetzung und zugehoeriges verfahren. | |
| DE3839825A1 (de) | Feststoffdispersionen enthaltend oxipurinol und/oder seine alkali- oder erdalkalisalze | |
| DE2145325A1 (de) | Verfahren zur Herstellung einer Arzneimittelz ubereitung | |
| DE2425764A1 (de) | Tabletten | |
| DE60120630T2 (de) | Pharmazeutische Zusammensetzung enthaltend Xanthangummi | |
| DE68907609T2 (de) | Arzneimittelzusammensetzung. | |
| DE60013583T2 (de) | Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs | |
| DE2451568A1 (de) | Verfahren zur herstellung von emulgierbaren pulverfoermigen produkten | |
| DE1810705C3 (de) | Stabilisierung von Vitaminen | |
| DE3509741A1 (de) | Orale dosierungsform von etoposid | |
| DE69311394T2 (de) | Arzneimittel verzögerter Wirkstoffabgabe | |
| DE1617309C3 (de) | Verfahren zur Herstellung von pharmazeutischen Präparaten mit Vitamingehalt |